オプションチェーンは、Expion360の株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Expion360の市場センチメントを評価します。.

Expion360 (NASDAQ:XPON) 株価情報, オプションチェーン

Expion360

Expion360 Inc is focused on the design, assembly, manufacturing, and sales of lithium iron phosphate (LiFePO4) batteries and supporting accessories for recreational vehicles (RV's) and marine applications with plans to expand into home energy storage products and industrial applications. Its product offerings include some of the minimal-footprint batteries in the RV & Marine industry.

Expion360 Inc

Xponential Fitness, Inc. Class A Common Stock

Xponential Fitness Inc

Barclays analyst Duffy Fischer maintains DuPont de Nemours (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DD#NYSE">DD</a>) with a Equal-Weight and lowers the price target from $89 to $73.

News

Price Target

Analyst Ratings

Barclays Maintains Equal-Weight on DuPont de Nemours, Lowers Price Target to $73

Combination treatment of TFF2 with anti-PD1 antibody was associated with the activation of cancer-killing CD8+ T Cells and limiting immune evasion by tumor cells
TNX-1700 is in preclinical development for gastric and colorectal cancers

Biotech

Events

General

TNXP

Tonix Pharmaceuticals Presented Preclinical Data On Gastric Cancer Models At AACR 2025 Annual Meeting

Cantor Fitzgerald analyst Steven Seedhouse initiates coverage on Korro Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRRO#NASDAQ">KRRO</a>) with a Overweight rating and announces Price Target of $74.

Initiation

KRRO

Cantor Fitzgerald Initiates Coverage On Korro Bio with Overweight Rating, Announces Price Target of $74

Schwab Retirement Plan Services (SRPS) today announced expanded student loan and college planning resources available to 401(k) plan participants through an agreement with Candidly, a leading student loan and education benefits platform.
The collaboration includes participant access to Candidly Core, a suite of tools and resources designed to help employees optimize their repayment strategy and save significant time and money as they work toward eliminating student loan debt. Candidly Core also offers college planning resources, including a 529 plan finder and calculators to help with decision making. Through an integrated online experience, participants have one-click access to Candidly resources directly from the SRPS participant website.
Expanded Student Loan Retirement Matching Capabilities
Schwab and Candidly are also offering an integrated solution for employers implementing a student loan retirement match for their 401(k) plans as allowed by the SECURE 2.0 Act. Through this collaboration, Candidly verifies that participants have properly completed the self-certification process, which allows them to confirm their qualified student loan payments, and provides that information to SRPS, which can then calculate the employer match and fulfill the contributions.

SCHW

Schwab Joins Forces with Candidly To Offer Expanded Education and Loan Assistance For 401(k) Participants

WIIM

WW International shares are trading higher after the company announced a pharmacy integration with Eli Lilly's LillyDirect pharmacy provider, Gifthealth.

ABEO

ABEO stock has given up its prior gain. Abeona Therapeutics shares were trading higher after the company announced FDA approval of ZEVASKYN for treating wounds in patients with recessive dystrophic epidermolysis bullosa.

Barclays analyst Nicholas Campanella maintains Chesapeake Utilities (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPK#NYSE">CPK</a>) with a Equal-Weight and lowers the price target from $125 to $124.

Barclays Maintains Equal-Weight on Chesapeake Utilities, Lowers Price Target to $124

WeightWatchers Announces Pharmacy Integration With Eli Lilly and Company's LillyDirect Pharmacy Provider, Gifthealth; Integration Streamlines Member Access To Zepbound Vials

<a href="https://www.benzinga.com/markets/cryptocurrency/25/04/45007049/bitcoin-etfs-see-442m-daily-inflow-as-btc-hovers-around-94000">U.S. spot bitcoin ETFs</a> recorded $591.3 million in net inflows on Monday, marking their seventh consecutive day of positive flows as Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) continues trading above $95,000.
What Happened: BlackRock&#8216;s BItcoin ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIT#NASDAQ">IBIT</a>) dominated the inflow activity, attracting $970.9 million in new investments while several competitors experienced outflows, according to <a href="https://sosovalue.com/assets/etf/us-btc-spot">data</a> from SoSoValue. 
Ark and 21Shares&#8216; (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKB#BATS">ARKB</a>) saw $226.3 million in outflows, while Fidelity&#8216;s (BATS:<a class="ticker" href="https://www.benzinga.com/stock/FBTC#BATS">FBTC</a>) recorded $86.9 million leaving the fund. 
Despite these mixed results across individual funds, the overall ETF market has shown remarkable strength in recent weeks. 
Last week saw $3 billion in total inflows, the highest weekly figure since November 2024, pushing cumulative net inflows to $39.02 billion—the highest level since Feb. 24.
The continued ETF demand comes as Bitcoin trades sideways at $95,130 after briefly surpassing $95,000 earlier on Monday. 
Total trading volume across the 12 ETFs reached $2.4 billion, down from $3.3 billion on Friday.
Meanwhile, spot Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) ETFs extended their own positive streak to three days, with $64.1 million in net inflows.
Read Also: <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/45048427/watch-this-bitcoin-indicator-to-know-if-a-run-to-100000-is-coming">Watch This Bitcoin Indicator To Know If A Run To $100,000 Is Coming</a>
Why It Matters: The strong institutional demand for Bitcoin through ETFs coincides with significant developments at the state government level. 
On Monday, the Arizona House of Representatives approved two bills that could establish the nation&#8217;s first state-level Bitcoin reserve. 
Senate Bill 1025, known as the <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/45058619/arizona-moving-to-convert-up-to-10-of-its-treasury-to-bitcoin-legislature-clears-bills-paving-way-for-strategic-crypto-reserve">Arizona Strategic Bitcoin Reserve Act</a>, passed with 31 votes in favor and 25 against, proposing to allocate up to 10% of the state treasury and retirement system funds to digital currencies, particularly Bitcoin.
A companion bill, SB1373, which would establish a state-level digital assets reserve, passed with broader support of 37-19. Both bills now head to Arizona Governor Katie Hobbs&#8216; desk for approval.
Arizona&#8217;s legislative push follows President Donald Trump&#8216;s <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43177482/trump-signs-executive-order-on-crypto-bitcoin-reserve-to-be-evaluated">establishment of a federal Bitcoin reserve</a> earlier this year, which will be funded through cryptocurrency recovered from criminal or civil asset forfeiture and &#8220;<a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43177482/trump-signs-executive-order-on-crypto-bitcoin-reserve-to-be-evaluated">budget-neutral strategies</a>.&#8221;
If Governor Hobbs signs the legislation, Arizona would become the first state to formally establish a cryptocurrency reserve, potentially setting a precedent for other states considering similar measures amid growing institutional adoption of digital assets.
Read Next:&nbsp;
<ul>
<li><a href="https://benzinga.com/markets/cryptocurrency/25/04/45039243/xrp-is-the-top-altcoin-bet-10x-research" target="_blank" rel="noreferrer noopener">XRP Is The Top Altcoin Bet: 10x Research</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

ARK 21Shares Bitcoin ETF ARK 21Shares Bitcoin ETF

ARKB

Fidelity Wise Origin Bitcoin Fund Fidelity Wise Origin Bitcoin Fund

FBTC

IBIT

Bitcoin Steady At $95,000 As US Bitcoin ETFs Record $591 Million Net Inflows

PAVS

Paranovus Entertainment Technology Regains Nasdaq Compliance

TALK

Talkspace Partners With Bark Technologies to Equip Teens with Essential Mental Health Resources Right From Their Bark Phones

Royal Caribbean Cruises Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>) shares are <a href="https://www.benzinga.com/premarket">trading higher in premarket</a> on Tuesday after the first-quarter fiscal 2025 earnings.
The cruise operator <a href="https://www.benzinga.com/pressreleases/25/04/n45061747/royal-caribbean-group-reports-first-quarter-results-and-increases-full-year-guidance">reported first-quarter sales growth of 7.2% </a>year-on-year to $4 billion, marginally missing the analyst consensus estimate of $4.01 billion.
Passenger ticket revenues rose 7.9% Y/Y to $2.74 billion compared to last year. Total cruise operating expenses were $2.07 billion versus $2.05 billion a year ago.&nbsp;
Gross Cruise Costs per Available Passenger Cruise Days (APCD) decreased 1.1%. Gross margin yields increased 13.9% as-reported, and net yields increased 4.7% in constant currency.
Operating income for the quarter jumped 26% to $945 million, with an operating margin of 23.6%. The occupancy rate in the quarter was 108.8% versus 107% last year.
Also Read: <a href="https://www.benzinga.com/news/25/04/45040811/marriott-bets-355m-on-trendy-citizenm-hotels-to-woo-modern-travelers">Marriott Bets $355M On Trendy CitizenM Hotels To Woo Modern Travelers</a>
Adjusted EBITDA for the quarter was $1.4 billion, with a margin of 35.1%. Adjusted EPS of $2.71 <a href="https://www.benzinga.com/earnings">beat the consensus estimate</a> of $2.54.
As of March 31, the group's customer deposit balance was $6.33 billion. Royal Caribbean held $386 million in cash and equivalents as of March-end.
Royal Caribbean CEO Jason Liberty said the company is navigating &#8220;the complexities of the current macroeconomic landscape&#8221; while also optimizing revenue and managing costs.
Outlook: Royal Caribbean expects FY25 net yields growth of 2.5%—4.5% in constant currency. RCL raises its FY25 adjusted EPS outlook from $14.35 – $14.65 to $14.55 &#8211; $16.55 versus an estimate of $14.94.
The company expects second-quarter adjusted EPS of $4.00 – $4.10, with an estimate of $3.96. Net yields for the first quarter are expected to increase 4.4% to 4.9% in constant currency.
Price Action:&nbsp;RCL shares traded higher by 4.48% at $226.00 in premarket at last check Tuesday.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/25/04/45039495/dominos-pizza-q1-operating-margin-shrinks-as-lower-income-consumers-feel-the-pinch">Domino&#8217;s Pizza Q1 Operating Margin Shrinks As Lower-Income Consumers Feel the Pinch</a></li>
</ul>
Image: Shutterstock

Movers & Shakers

Royal Caribbean Cruises' Q1 Benefits From Strong Demand, Stock Surges

Barclays analyst David Strauss maintains CACI International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CACI#NYSE">CACI</a>) with a Overweight and raises the price target from $450 to $510.

CACI

Barclays Maintains Overweight on CACI International, Raises Price Target to $510

A rare and historically reliable bullish signal just flashed on Wall Street, and if history is any guide, the next few months could deliver double-digit gains <a href="https://www.benzinga.com/topic/expert-ideas">for the S&amp;P 500. </a>
In a note shared last week, Bank of America technical analyst Paul Ciana said the latest "breadth thrust" marked the fourth bullish signal for the S&amp;P 500 this year, potentially clearing the runway for a move toward 6,000 by year-end.
<h3 class="wp-block-heading">What's a Breadth Thrust And Why It Matters</h3>
A breadth thrust is a technical indicator used to identify the beginning of a new bull market or the acceleration of an existing uptrend. Rather than focusing on index levels, it looks at market breadth, which refers to the percentage of stocks participating in a rally.
&#8220;A breadth thrust means market breadth has improved from weak to strong over a short period of time,&#8221; Ciana wrote.
The most widely accepted definition comes from financial analyst Marty Zweig, who stated that a breadth thrust occurs when the 10-day moving average of advancing stocks divided by the total number of stocks rises from below 40% to above 61.5% within 10 trading days.
That happened on April 24, when the S&amp;P 500 closed at 5,484.77, confirming the 32nd such signal since 1927.
"Since 1939, the S&amp;P 500 was higher 100% of the time — 16 out of 16 — following a breadth thrust in both 130 and 190 trading days," Ciana said, adding that average returns stood at 17.1% and 19.6%, respectively.
&#8220;If the SPX falls below 5,484.77 in the second quarter – a risk from the death cross signal – then the breadth thrust signal favors buying,&#8221; the analyst added. 
<h3 class="wp-block-heading">What History Tells Us About Breadth Thrusts</h3>
Since 1939, breadth thrusts have been extremely reliable forward indicators. The table below summarizes how the S&amp;P 500 performed after the last 16 such signals:
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Days After Signal</th>
<th>% Times Up</th>
<th>Avg Return</th>
</tr>
</thead>
<tbody>
<tr>
<td>130</td>
<td>100%</td>
<td>+17.1%</td>
</tr>
<tr>
<td>190</td>
<td>100%</td>
<td>+19.6%</td>
</tr>
<tr>
<td>250</td>
<td>93.8%</td>
<td>+21.3%</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">Four Bullish Signals Light The Way</h3>
Bank of America now counts four recent technical indicators supporting a positive outlook for stocks, despite what it calls a &#8220;cyclical bear period&#8221; resembling the choppy years of 2022, 2018, 2015 and 2005.
The signals include:
<ul>
<li>A VIX volatility index spike above 45.</li>
<li>An NYSE 90% up day, where 90% of stocks advanced on a substantial volume (occurred on April 9, 2025).</li>
<li>An SPX death cross, a traditionally bearish event that in this case sets up a contrarian buy-the-dip opportunity.</li>
<li>The April 24 breadth thrust, now considered a powerful bullish confirmation.</li>
</ul>
Despite these bullish signals, the S&amp;P 500 is still grappling with technical hurdles. The index currently trades below its 200-day simple moving average, which sits around 5,746. 
Ciana indicated that a &#8220;cup and handle-like&#8221; base may be forming, with the potential to lift the index back toward its year-to-date highs. Yet, a drop below &#8220;the bull gap at 5,356-5,309&#8221; could invalidate this setup, making near-term market action crucial.
A push above 5,500-5,571 would favor a bullish wave count, projecting the index toward 6,000.
On Tuesday, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) traded at $550, or about 10% below its all-time high of $613.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/04/45058829/jim-cramer-dismisses-recession-panic-says-tariffs-may-sting-but-too-many-jobs-for-economy-to-derail">Jim Cramer Dismisses Recession Panic: Says Tariffs May Sting, But Too &#8216;Many Jobs&#8217; For Economy To &#8216;Derail&#8217;</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Equities

Broad U.S. Equity ETFs

Technicals

Trading Ideas

ETFs

Rare Bullish Signal Just Flashed On Wall Street: Will It Power S&P 500 To 6,000?

Morgan Stanley analyst Brian Harbour maintains Domino's Pizza (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NASDAQ">DPZ</a>) with a Overweight and raises the price target from $492 to $510.

Morgan Stanley Maintains Overweight on Domino's Pizza, Raises Price Target to $510

Visa Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) will release earnings results for the second quarter, after the <a href="https://www.benzinga.com/quote/V/earnings">closing bell on Tuesday, April 29</a>.
Analysts expect the San Francisco, California-based company to report quarterly earnings at $2.68 per share, up from $2.51 per share in the year-ago period. Visa projects to report quarterly revenue at $9.55 billion, compared to $8.78 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Visa has reportedly proposed a $100 million payment to Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) to secure the Apple Card network. This move comes amid fierce competition among the country's leading payment networks.
Visa shares gained 0.7% to close at $337.51 on Monday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/V/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Barclays analyst Ramsey El-Assal maintained an Overweight rating and raised the price target from $361 to $396 on Feb. 3, 2025. This analyst has an accuracy rate of 65%.</li>
<li>BMO Capital analyst Rufus Hone maintained an Outperform rating and increased the price target from $350 to $370 on Jan. 31, 2025. This analyst has an accuracy rate of 72%.</li>
<li>Mizuho analyst Dan Dolev maintained a Neutral rating and boosted the price target from $304 to $359 on Jan. 31, 2025. This analyst has an accuracy rate of 66%.</li>
<li>JP Morgan analyst Tien-Tsin Huang maintained an Overweight rating and increased the price target from $340 to $375 on Jan. 31, 2025. This analyst has an accuracy rate of 65%.</li>
<li>Goldman Sachs analyst Matthew O'Neill maintained a Buy rating and raised the price target from $346 to $384 on Jan. 31, 2025. This analyst has an accuracy rate of 63%.</li>
</ul>
Considering buying Visa stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="599" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29031605/image-203-1024x599.png" alt="" class="wp-image-892185" style="width:534px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29031605/image-203-1024x599.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29031605/image-203-300x175.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29031605/image-203-768x449.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29031605/image-203.png 1105w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45038052/top-2-industrials-stocks-that-may-fall-off-a-cliff-this-quarter">Top 2 Industrials Stocks That May Fall Off A Cliff This Quarter</a> </li>
</ul>
Photo via Shutterstock

Earnings

Markets

AAPL

Top Wall Street Forecasters Revamp Visa Expectations Ahead Of Q2 Earnings

Buybacks

RVSB

Riverview Bancorp Board Adopts Repurchase Program Up To $2M

JP Morgan analyst Tien-Tsin Huang maintains Cognizant Tech Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSH#NASDAQ">CTSH</a>) with a Neutral and lowers the price target from $92 to $81.

CTSH

JP Morgan Maintains Neutral on Cognizant Tech Solns, Lowers Price Target to $81

<ul>
<li>Orchestra BioMed's Virtue&#xAE; Sirolimus AngioInfusion Balloon&#x2122;("Virtue SAB") is the only non-coated drug-eluting balloon system under clinical investigation worldwide and has been awarded multiple FDA Breakthrough Device Designations</li>
<li>The Virtue Trial will be the first U.S. IDE head-to-head randomized evaluation of a sirolimus-eluting balloon versus a commercially available paclitaxel-coated balloon (AGENT&#x2122;) for the treatment of coronary in-stent restenosis ("ISR")</li>
<li>Robust non-inferiority trial is designed to provide a clear pathway to regulatory approval as well as potentially showcase clinical advantages of Virtue SAB</li>
<li>With the amended IDE approved by the FDA, Orchestra BioMed is currently targeting initiation of the Virtue Trial during the second half of 2025</li>
</ul>
NEW HOPE, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OBIO#NASDAQ">OBIO</a>, "Orchestra BioMed" or the "Company"))), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that the U.S. Food and Drug Administration ("FDA") has approved its Investigational Device Exemption ("IDE") amendment to initiate an updated design of the Company's planned Virtue SAB in the Treatment of Coronary ISR Trial ("Virtue Trial"). The IDE provides FDA regulatory clearance for Orchestra BioMed to initiate a U.S. pivotal clinical trial comparing its highly differentiated, next-generation Sirolimus-AngioInfusion Balloon, Virtue SAB to the Boston Scientific AGENT paclitaxel-coated balloon, currently the only drug-coated balloon ("DCB") FDA-approved for a coronary indication. Data from the Virtue Trial will be used to support regulatory approval in the U.S. Virtue SAB and SirolimusEFR are investigational technologies owned by Orchestra BioMed, which also controls and is responsible for all regulatory filings, clinical operations, and drug and device supplies for the Virtue Trial.

Orchestra BioMed Holdings, Inc. - Ordinary Shares

OBIO

Orchestra BioMed Holdings: FDA Approves IDE Amendment To Initiate Updated Design Of Virtue SAB In Treatment Of Coronary ISR Trial

In the preceding three months, 9 analysts have released ratings for Traeger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COOK#NYSE">COOK</a>), presenting a wide array of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $2.94, a high estimate of $5.00, and a low estimate of $2.00. Highlighting a 25.38% decrease, the current average has fallen from the previous average price target of $3.94. 
<img src="https://www.benzinga.com/files/images/story/2025/1745931752_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The perception of Traeger by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;---------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Brian McNamara &#x7C;Canaccord Genuity &#x7C;Lowers &#x7C;Buy &#x7C; $3.00&#x7C;$5.00 &#x7C; 
&#x7C;Joseph Feldman &#x7C;Telsey Advisory Group&#x7C;Maintains &#x7C;Market Perform &#x7C; $2.50&#x7C;$2.50 &#x7C; 
&#x7C;Megan Alexander &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Underweight &#x7C; $2.50&#x7C;$3.00 &#x7C; 
&#x7C;Nik Modi &#x7C;RBC Capital &#x7C;Lowers &#x7C;Sector Perform &#x7C; $2.00&#x7C;$2.75 &#x7C; 
&#x7C;Peter Keith &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Neutral &#x7C; $2.50&#x7C;$3.75 &#x7C; 
&#x7C;Peter Benedict &#x7C;Baird &#x7C;Lowers &#x7C;Neutral &#x7C; $2.50&#x7C;$3.50 &#x7C; 
&#x7C;Brian McNamara &#x7C;Canaccord Genuity &#x7C;Lowers &#x7C;Buy &#x7C; $5.00&#x7C;$7.00 &#x7C; 
&#x7C;Joseph Feldman &#x7C;Telsey Advisory Group&#x7C;Lowers &#x7C;Market Perform &#x7C; $2.50&#x7C;$4.00 &#x7C; 
&#x7C;Joseph Feldman &#x7C;Telsey Advisory Group&#x7C;Maintains &#x7C;Outperform &#x7C; $4.00&#x7C;$4.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Traeger. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Traeger compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Traeger's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/COOK/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Traeger analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>About Traeger</h2>
Traeger Inc designs, sources, sells, and supports wood pellet fueled barbeque grills sold to retailers, distributors, and direct to consumers. It produces and sells the pellets used to fire the grills and also sells Traeger-branded rubs, spices, and sauces, as well as grilling accessories including covers, barbeque tools, trays, liners, and merchandise. The company's geographical segments include North America and the Rest of the world, of which majority of revenue is from North America.
<h3>Breaking Down Traeger's Financial Performance</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Traeger's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 3.16%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -4.13%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Traeger's ROE excels beyond industry benchmarks, reaching -2.5%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Traeger's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -0.84%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Traeger's debt-to-equity ratio surpasses industry norms, standing at 1.57. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

Expion360

Expion360 (XPON) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル